公开(公告)号：US20220235117A1

公开(公告)日：2022-07-28

申请号：US17613322

申请日：2020-05-22

Applicant: XIAMEN UNIVERSITY ,  YANG SHENG TANG COMPANY, LTD.

Inventor： Wenxin LUO ,  Can WEN ,  Xinchu XIANG ,  Jixian TANG ,  Yangtao WU ,  Tianying ZHANG ,  Quan YUAN ,  Ningshao XIA

IPC: C07K16/08 ,  A61P31/20

Abstract: Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.

公开(公告)号：US20190389939A1

公开(公告)日：2019-12-26

申请号：US15766593

申请日：2016-10-09

Applicant: XIAMEN UNIVERSITY ,  YANG SHENG TANG COMPANY, LTD.

Inventor： Wenxin LUO ,  Bing ZHOU ,  Juan ZHANG ,  Quan YUAN ,  Tianying ZHANG ,  Jun ZHANG ,  Ningshao XIA

IPC: C07K16/08

Abstract: The invention provides an antibody (in particular, a humanized antibody) against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a method for preparing the same, and a pharmaceutical composition comprising the same. The invention also provides use of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition according to the invention can be used for preventing and/or treating HBV infection or a disease associated with HBV infection (such as Hepatitis B), for neutralizing HBV virulence in a subject (such as human), or for reducing the serum level of HBV DNA and/or HBsAg in a subject.

公开(公告)号：US20250101083A1

公开(公告)日：2025-03-27

申请号：US18832696

申请日：2023-01-20

Applicant: XIAMEN UNIVERSITY ,  YANG SHENG TANG COMPANY, LTD.

Inventor： Wenxin LUO ,  Yue WANG ,  Yaxian MEI ,  Zhenghong AO ,  Yuanzhi CHEN ,  Jixian TANG ,  Yichao JIANG ,  Xiaoqing CHEN ,  Tianying ZHANG ,  Quan YUAN ,  Ningshao XIA

IPC: C07K16/08 ,  A61K39/00 ,  A61P31/20 ,  C07K14/005 ,  C12N15/85

Abstract: The present invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection treatment. In particular, the present invention relates to an epitope peptide (or a variant thereof) capable of treating a hepatitis B virus infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and an antibody (e.g. a nanobody) for the epitope peptide. The epitope peptide and antibody of the present invention can be used to prevent and/or treat HBV infection or a disease related to HBV infection (e.g. hepatitis B), for reducing the serum level of HBV DNA and/or HBsAg in a subject (e.g. a human), or for activating a subject (e.g. a chronic HBV infected person or a chronic hepatitis B patient) against HBV humoral immune response.

公开(公告)号：US20220251173A1

公开(公告)日：2022-08-11

申请号：US17613392

申请日：2020-05-22

Applicant: XIAMEN UNIVERSITY ,  YANG SHENG TANG COMPANY, LTD.

Inventor： Wenxin LUO ,  Yichao JIANG ,  Chao YU ,  Xiaoqing CHEN ,  Jixian TANG ,  Quan YUAN ,  Tianying ZHANG ,  Ningshao XIA

IPC: C07K16/08 ,  A61P31/20

Abstract: Antibodies (especially humanized antibodies) against the hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding same, a method for preparing same, and a pharmaceutical composition containing same. The anti-HBsAg antibodies have a higher binding affinity to HBsAg at a neutral pH than at an acidic pH, thereby significantly enhancing virus clearance efficiency and prolonging virus inhibition time. The antibodies and pharmaceutical composition may be used to prevent and/or treat HBV infections or diseases related to HBV infection (such as hepatitis B) for use in neutralizing the virulence of HBV in the body of a subject (such as a human) to reduce a serum level of HBV DNA and/or HBsAg in the body of the subject, or to activate a humoral immune response of a subject (such as a person infected with chronic HBV or a patient who has chronic hepatitis B) against HBV.

公开(公告)号：US20160145320A1

公开(公告)日：2016-05-26

申请号：US14781391

申请日：2014-04-02

Applicant: XIAMEN UNIVERSITY

Inventor： Yixin CHEN ,  Qingbing ZHENG ,  Rui LI ,  Chenguang SHEN ,  Shaojun KE ,  Wenxin LUO ,  Honglin CHEN ,  Ningshao XIA

IPC: C07K16/10 ,  G01N33/569

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/11 ,  G01N2469/10

Abstract: The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.

Abstract translation: 本发明涉及识别流感病毒血凝素（HA）蛋白HA1结构域上的抗原表位的抗体，用于产生抗体的细胞系及其用途。 根据本发明的抗体可以特异性结合不同HA亚型的HA1结构域，并特异性结合H1亚型（包括季节性H1N1和2009大流行H1N1）和流感病毒H5亚型的血凝素（HA）蛋白的HA1结构域。 因此，本发明还涉及用于预防和/或治疗H1亚型和H5亚型流感病毒感染的疫苗或药物组合物和/或由包含本发明的抗体的感染（例如流感）引起的疾病。